Navigation Links
GW Pharmaceuticals plc Reports 2013 Q4 and Full Year Financial Results
Date:11/19/2013

purified extract of Cannabidiol, or CBD)
  • FDA orphan drug designation granted by FDA for Epidiolex in Dravet syndrome
  • Seven physician-led INDs granted by FDA to treat 125 pediatric epilepsy patients in the U.S. with Epidiolex
  • Epidiolex pediatric epilepsy clinical trials in planning for 2014
  • Additional epilepsy pipeline candidate, GWP42006 (Cannabidivarin or CBDV), commenced Phase 1 trial in September 2013
  • Significant clinical activity for GW's other cannabinoid pipeline product candidates, including:
  • Positive preliminary data reported from a Phase 2a exploratory clinical trial of the novel cannabinoid medicine GWP42004 in type-2 diabetes with a Phase 2 dose ranging trial expected to commence in early 2014
  • Phase 2 trial of GWP42003 for the treatment of ulcerative colitis on-going with data expected in the first half of 2014
  • Phase 2 trial of GWP42003 for the treatment of schizophrenia expected to commence in the first half of 2014
  • Phase 1b/2a trial of THC:CBD for the treatment of glioma commenced in November 2013
  • Financial Highlights

  • Total revenue for 2013 of £27.3m ($44.2m) compared to £33.1m in 2012. 2012 revenues included a £9.8m milestone receipt compared to £0.3m milestone income in 2013.
  • Net loss after tax for 2013 of £4.5m ($7.4m) compared to a profit after tax of £2.5m in 2012, which primarily reflected the impact of the £9.8m milestone payment received last year.
  • Cash and cash equivalents at 30 September 2013 of £38.1m ($61.6m) compared to £29.3m as at 30 September 2012.
  • "This was a transformative year for GW with the successful completion of an IPO on NASDAQ, progress with two Phase 3 programs for Sativex in the United States, and the emergence of a new exciting orphan development program in childhood epilepsy," stated Justin Gover, GW's Chief Executive Officer. "We believe that th
    '/>"/>

    SOURCE GW Pharmaceuticals plc
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
    2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
    3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
    4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
    5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
    6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
    7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
    8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
    9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
    10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
    11. Avanir Pharmaceuticals To Present at Three Conferences In May
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
    (Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
    (Date:1/14/2014)... Jan. 14, 2014 InformEx, North America,s ... high-value chemistry, will hold the 30 th edition of ... Convention Center from January 21-24. (Logo: ... top pharmaceutical, fine chemical and specialty chemical companies will take ...
    Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
    (Date:4/17/2014)... An international team led by researchers at UC ... which plays a key role in cell division, also ... is the first time the complex has been shown ... cyclin B1/Cdk1 an excellent target to control cellular energy ... research was published online today in the journal ...
    (Date:4/17/2014)... find a colored ribbon representing a disease. A pink ribbon ... ribbon does one think of with lung cancer?, Although white ... from the disease, black may be the only one they ... cancer patients, primarily smokers between the ages of 51 to ... often felt by these patients, the emotional toll it can ...
    (Date:4/17/2014)... A new study has found that India,s shocking rates ... debt-ridden farmers who are clinging to tiny smallholdings ... ,cash crops, such as cotton and coffee, that are ... supports a range of previous case studies that point ... sector following the ,liberalisation, of the nation,s economy during ...
    (Date:4/17/2014)... anti-malarial treatment that lost its status as the leading ... new lease of life, with new research indicating it ... could revive the use of the cheap anti-malarial drug ... claims the lives of more than half a million ... that causes malaria has developed resistance to chloroquine, but ...
    (Date:4/16/2014)... HAMPTON, NJ (April 16, 2014): Celldex Therapeutics, Inc. ... Phase 1 study of CDX-1401 in solid tumors, including ... Translational Medicine (Vol 6 Issue 232). The data ... of clinical benefit in patients with very advanced cancers ...
    Breaking Medicine News(10 mins):Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:Unraveling the 'black ribbon' around lung cancer 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 3Health News:Scientists find new way to fight malaria drug resistance 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4
    ... becoming apparent to the Government Health officials, albeit for the ... socks and gearing up to take stock of multi-drug resistant ... a public health initiative , developed by the World Health ... in Maharashtra and Gujarat. 100 MDR-TB cases are envisaged in ...
    ... at The University of Texas M. D. Anderson Cancer ... prostate cancer patients who are eligible for watchful // ... ,"With the advent of the PSA test, we ... no evidence that early detection means longer survival. Because ...
    ... recent progress in echocardiography providing doctors with improved imaging ... a // probe into the esophagus, which emits radio ... in enabling a motion picture of the heart, far ... images are capable of offering various options to doctors ...
    ... women who present to the sex clinic only report ... some women, may present with just the opposite complaints//. ... suffering from the so-called persistent sexual arousal syndrome (PSAS) ... ,Currently, very little is understood about this rare syndrome ...
    ... you badly in need of blood or are you inclined in ... it//? Either way, the solution for it is just a few ... simple yet amazingly useful venture in 2000. He works for Central ... of the venture too. ,If you're located in Kolkata ...
    ... is a mere 0.028 percent as compared to the national ... further, the military's top doctor said Thursday. ,"Contracting ... crime," Surgeon Vice Admiral Vijay K. Singh, director general of ... ,The national average of the incidence of HIV/AIDS ...
    Cached Medicine News:Health News:New Network To Ease Blood donation In India 2Health News:Incidence Of HIV/AIDS In The Indian Armed Forces Negligible 2
    Lyphochek Therapeutic Drug Monitoring Control (TDM) contains over 40 analytes with assayed values at three clinically significant levels....
    Lyphochek Urine Metals Control incorporates two levels of critical trace elements, heavy metals and organic metabolites, and is ideal for environmental and industrial testing....
    Liquichek Whole Blood Volatiles Control is an assayed liquid control for monitoring volatile compounds. This product is available in 2 levels....
    Lyphochek Urine Bone Markers Control is a bilevel human urine based control designed to monitor tests for urinary markers of osteoporosis management and bone resorption....
    Medicine Products: